Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8152W HIGH $25.95
Volume
539.01 K
Value Traded
6.79 M
Short % Float
10.43%
Days to Cover
3.9
-10.25%Week
-30.5%1 Month
-77.24%3 Month
-71.39%6 Month
-26.18%5 Year
-26.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
229.03 M
EPS (TTM)
-2.06
P/E Ratio
-
Ent. Value
-152.22 M
Total Shares
45.87 M
Float Shares
31.40 M
Insiders
31.58%
Institutions
61.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BIOA Catalyst Timeline
Dated clinical, regulatory and corporate events for BioAge Labs, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioAge Labs, Inc.
139Total events
5Upcoming
53Tier-1 (high impact)
2024 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
BioAge to participate in ROTH Healthcare Opportunities Conference one-on-one meetings
▲First Patient DosedBGE-102Trial
First participant dosed in QUELL-DME Phase 2 trial of BGE-102 in DME
Diabetic Macular Edemasource ↗
▲First Patient DosedBGE-102Trial
First patient dosed in Phase 2 proof-of-concept study QUELL-CV for BGE-102
cardiovascular risk reductionsource ↗
▲First Patient DosedBGE-102Trial
First participant dosed in QUELL-CV Phase 2 trial of BGE-102
cardiovascular risk reductionsource ↗
●Trial InitiationBGE-102Trial
QUELL-DME Phase 1b/2a trial planned to initiate in mid-2026
diabetic macular edemasource ↗
◆Topline ReadoutBGE-102Clinical Data
Topline data from Phase 1 SAD/MAD trial including additional MAD cohorts
elevated cardiovascular risksource ↗
▲First Patient DosedBGE-102Trial
First participant dosed in QUELL-CV Phase 2 trial of BGE-102
obesity and inflammation at elevated cardiovascular risksource ↗
◆PDUFA DateRegulatory Filing
PDUFA date for sBLA of subcutaneous starting dose with Leqembi Iqlik
early Alzheimer's diseasesource ↗
◆Oral PresentationBGE-102Presentation
Phase 1 clinical data presentation for BGE-102 at R&D Day
atherosclerotic cardiovascular diseasesource ↗
▲Full ResultsBGE-102Clinical Data
Phase 1 results for BGE-102 reported
obesity with elevated inflammationsource ↗
◆Oral PresentationPresentation
BioAge Labs to present at 25th Annual Needham Virtual Healthcare Conference
◆Topline ReadoutBGE-102Clinical Data
Topline data from QUELL-CV anticipated
obesity and elevated baseline inflammationsource ↗
◆Trial InitiationBGE-102Trial
Phase 2 cardiovascular risk proof-of-concept trial initiation
cardiovascular risksource ↗
●Oral PresentationlecanemabPresentation
Oral presentation on lecanemab binding profile at AD/PD 2026
Alzheimer's diseasesource ↗
●Poster PresentationexidavnemabPresentation
Poster on SAA screening strategy in exidavnemab trial at AD/PD 2026
Parkinson's disease and multiple system atrophysource ↗
◆Oral PresentationPresentation
BioAge Labs to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▼Equity OfferingCorporate
Pricing of upsized $115.0 million public offering of 5,897,435 shares at $19.50 per share
▼Equity OfferingCorporate
Proposed underwritten public offering of up to $75.0 million of common stock
▲Interim AnalysisBGE-102Trial
Additional positive interim Phase 1 data for BGE-102 MAD cohort in obese individuals with elevated hsCRP
cardiovascular risk factorssource ↗
▲Patent GrantedBGE-102IP / Competition
Patent issued covering additional composition of matter and novel NLRP3 binding site for BGE-102
◆Topline ReadoutBGE-102Clinical Data
Topline data from Phase 1 SAD/MAD trial of BGE-102 anticipated
cardiovascular risk and retinal diseasessource ↗
▲Priority ReviewRegulatory Filing
Priority Review granted for sBLA of Leqembi Iqlik subcutaneous starting dose
early Alzheimer's diseasesource ↗
▲NMPA NDA ApprovalLeqembiFiledEx-US Regulatory
BLA for subcutaneous formulation of Leqembi accepted in China and designated for priority review
early Alzheimer's diseasesource ↗
◆Full ResultsBGE-102Clinical Data
Full Phase 1 data anticipated including additional MAD cohorts in obese participants with elevated hsCRP
cardiovascular risk factorssource ↗
◆Trial InitiationBGE-102Trial
Phase 2a proof-of-concept trial in cardiovascular risk planned to initiate
cardiovascular risksource ↗
▲Interim AnalysisBGE-102Trial
Additional positive interim Phase 1 data from first MAD cohort in participants with obesity and elevated hsCRP
obesity with elevated hsCRPsource ↗
◆Topline ReadoutBGE-102Clinical Data
Initial SAD data for BGE-102 Phase 1 trial
obesity and cardiovascular risk factorssource ↗
▲Interim AnalysisBGE-102Trial
Positive interim Phase 1 data for BGE-102
cardiovascular risk factorssource ↗
▲Enrollment UpdateBGE-102Trial
Expansion of Phase 1 trial to include MAD cohorts in obese participants with elevated hsCRP
obesity with elevated hsCRPsource ↗
▲Interim AnalysisBGE-102Trial
Positive interim Phase 1 data for BGE-102 demonstrating reductions in inflammatory biomarkers
cardiovascular risksource ↗
◆Oral PresentationPresentation
BioAge Labs to present at Jefferies Global Healthcare Conference in London
●NDA SubmissionLeqembiFiledRegulatory Filing
NDA for subcutaneous formulation of Leqembi submitted in Japan
early Alzheimer's diseasesource ↗
▲First Patient DosedBGE-102Trial
First participant dosed in Phase 1 trial of BGE-102
obesity and cardiovascular risk factorssource ↗
◆Topline ReadoutAzelapragClinical Data
Top-line results from Phase 2 STRIDES trial of azelaprag in combination with tirzepatide
obesitysource ↗
Past FDA Catalysts and PDUFA Decisions
How BIOA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | BGE-102 (oral, brain-penetrant small-molecule NLRP3 inhibitor) | Phase 1b/2a data readout | Phase 1b/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 26%
Micro Cap(rank 172 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BGE-102 Small moleculeNCT07656727 | Obesity and Cardiovascular Risk | Phase 2 | ACTIVE NOT_RECRUITING | 160 | Dec 1, 2026 | ||||||
| BGE-102 Small moleculeNCT07812090 | Diabetic Macular Edema (DME) | Phase 2 | RECRUITING | 180 | Dec 1, 2027 | ||||||
| Azelaprag Small moleculeCompletedNCT06141889 | Undisclosed | Phase 1 | COMPLETED | 16 | Feb 2, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every BIOA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BGE-102 | obesity and elevated baseline inflammation | Phase 2 | 2026-08-05 | up to 98% suppression of IL-1β; median hsCRP reductions of 86% from baseline at both 60 mg and 120 mg once dailyRead More | BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Barton ShaneOfficer (Principal Accounting Officer) | Option | 4,290 4,290 held | $10.85 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BIOA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 2.9 % (93.3 %) | 56.22 M | 2.29 M |
BIOA Institutional Ownership Trends
BIOA Short Interest
Shares sold short, counted twice a month.
10.43%
Short % of Float
of tradable shares sold short
3.3M
Shares Sold Short
+6.5% vs prior count
3.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
830.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BIOA ranks across every disease it competes in
Competitive Position is a premium feature
See how BIOA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBIOA News
BIOABioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs, Inc. will participate in two upcoming investor conferences, the ROTH Healthcare Opportunities Conference and the Stifel Virtual Cardiometabolic Forum. Key executives will engage in one-on-one meetings and a fireside chat to discuss the company's developments. BioAge is focused on therapies for cardiometabolic diseases, with significant data expected in the near future.
Read more →BIOABioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
BioAge Labs has initiated the QUELL-DME Phase 2 trial, dosing its first participant with BGE-102, an oral NLRP3 inhibitor, for diabetic macular edema. The trial will assess BGE-102 both as a standalone treatment and in combination with anti-VEGF therapy. Primary results are expected in late 2027, with implications for other retinal diseases.
Read more →BIOABioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
BioAge Labs reported its second quarter 2026 financial results, highlighting the dosing of the first participant in the QUELL-CV Phase 2 trial for BGE-102. The company anticipates topline data in the second half of 2026 and plans to initiate QUELL-DME, a Phase 1b/2a trial, in mid-2026. Despite a net loss of $26.1 million, BioAge maintains a strong cash position to support ongoing and future trials.
Read more →BIOAHitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
BioAge Labs has initiated dosing in the Phase 2 QUELL-CV trial for BGE-102, an oral NLRP3 inhibitor aimed at reducing cardiovascular risk. This follows promising Phase 1 results that indicated significant reductions in hsCRP levels. The trial is designed to optimize dosing for future Phase 3 studies, with results expected later in 2026.
Read more →BIOABioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
BioAge Labs has initiated the QUELL-CV trial, dosing its first participant with BGE-102, a novel oral NLRP3 inhibitor aimed at reducing cardiovascular risk. This Phase 2 proof-of-concept trial will evaluate the drug's efficacy in participants with elevated systemic inflammation. Topline data is expected in the second half of 2026, building on promising Phase 1 results.
Read more →BIOABioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
BioAge Labs reported positive Phase 1 data for its NLRP3 inhibitor BGE-102, showing significant reductions in cardiovascular risk biomarkers. The company plans to initiate two proof-of-concept trials in mid-2026. Additionally, BioAge completed a successful public offering, raising $132.3 million to support its development programs. However, the company also reported a net loss of $22.3 million for the first quarter of 2026.
Read more →BIOABioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
BioAge Labs, Inc. announced it will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, a novel NLRP3 inflammasome inhibitor. The event will include insights from leading experts on its therapeutic implications for atherosclerotic cardiovascular disease (ASCVD) and retinal disease. Following the presentations, there will be a live Q&A session, aimed at engaging with attendees and discussing the latest developments in NLRP3 biology. The webcast will be accessible via their investor relations website and is positioned to enhance understanding of BGE-102’s potential in clinical settings.
Read more →BIOABioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
BioAge Labs reported promising Phase 1 clinical trial results for its novel oral NLRP3 inhibitor, BGE-102, which achieved significant reductions in high-sensitivity C-reactive protein (hsCRP) among participants with obesity and inflammation. The study demonstrated a well-tolerated profile, with both 60 mg and 120 mg doses achieving impressive biomarker reductions. Looking ahead, BioAge plans to initiate Phase 2 trials focused on cardiovascular risk and diabetic macular edema by mid-2026 and mid-2027, respectively, aiming to leverage BGE-102's potential across various indications.
Read more →BIOABioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
BioAge Labs, a clinical-stage biotechnology company, announced its participation in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. CEO Kristen Fortney will engage in a fireside chat, while other executives will hold one-on-one meetings. The company is advancing its lead product candidate, BGE-102, which is currently in a Phase 1 trial.
Read more →BIOA▼ -13.5%on this news
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
BioAge Labs reported positive interim Phase 1 data for BGE-102, a new NLRP3 inhibitor, highlighting its potential for cardiovascular risk reduction. The company plans to initiate a Phase 2a trial in 2026 and has expanded BGE-102's indication to ophthalmology, targeting diabetic macular edema. Additionally, BioAge completed a $132.3 million follow-on public offering, strengthening its financial position despite a reported net loss of $80.6 million for 2025. The results and upcoming trials suggest a robust pipeline and ongoing clinical development.
Read more →BIOANew data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
At the 2026 AD/PD congress, BioArctic and Eisai presented new data on lecanemab, highlighting a significant 78.4% treatment persistence rate at 18 months among early Alzheimer's patients. The findings align with previous Phase 3 study outcomes, suggesting that long-term treatment can lead to better clinical results. Additionally, BioArctic showcased an innovative screening strategy for their exidavnemab trial.
Read more →BIOABioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
BioAge Labs, a clinical-stage biotechnology company, announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will take part in a fireside chat on February 26, alongside CFO Dov Goldstein who will meet with investors. The company is focused on developing therapeutic candidates targeting metabolic diseases, with its lead product, BGE-102, currently in Phase 1 clinical trials.
Read more →BIOA▼ -5.6%on this news
BioAge Announces Proposed Public Offering
BioAge Labs, Inc. has announced a proposed public offering to raise up to $75 million in common stock, with an additional option for underwriters to purchase $11.25 million more. The funds will support research and development of its product candidates, including BGE-102. The offering is subject to market conditions and regulatory approvals.
Read more →BIOA▼ -5.6%on this newsshared move
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
BioAge Labs, Inc. has announced the pricing of an upsized public offering, raising approximately $115 million through the sale of nearly 5.9 million shares at $19.50 per share. The offering is scheduled to close on January 23, 2026. Funds raised will support research, clinical development, and manufacturing of their product candidates, particularly BGE-102. BioAge's efforts focus on addressing metabolic diseases linked to human aging through innovative therapies.
Read more →BIOA▲ +5.8%on this newsshared move
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
BioAge Labs has announced the expansion of its BGE-102 program into ophthalmology, focusing on a proof-of-concept study for diabetic macular edema (DME). The oral NLRP3 inhibitor has shown promising tolerability and anti-inflammatory effects in ongoing trials. The Phase 1b/2a trial is set to begin in mid-2026, with results expected by mid-2027.
Read more →BIOA▲ +15.9%on this news· ran to +28% by day 1
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
BioAge Labs announced positive interim results from its Phase 1 trial of BGE-102, a novel NLRP3 inhibitor. The trial showed an 86% reduction in hsCRP levels among obese participants with elevated cardiovascular risk. Additionally, BGE-102 demonstrated significant reductions in IL-6 and fibrinogen, with a favorable safety profile. The company plans to advance BGE-102 into a Phase 2a study in the first half of 2026.
Read more →BIOA▲ +13.9%on this news· ran to +31% by day 3
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BioAge reported positive interim Phase 1 data for BGE-102, a brain-penetrant NLRP3 inhibitor. The drug achieved 90 to 98 percent suppression of IL-1β at doses of 60 mg and higher. It also exceeded target levels in cerebrospinal fluid, indicating strong central nervous system penetration. The company is expanding the trial to include obese participants, with results expected in the first half of 2026.
Read more →BIOABioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
BioAge Labs, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025. CEO Kristen Fortney and CFO Dov Goldstein will engage in a fireside chat and one-on-one meetings. The company is focused on developing therapies for metabolic diseases, with its lead candidate BGE-102 currently in a Phase 1 trial.
Read more →About BioAge Labs, Inc.
Headquarters5885 HOLLIS STREET, EMERYVILLE, CA, 94608
BIOPHARMAWATCH ELITE PLUS
Trade the next BIOA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime